QNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quoin Pharmaceuticals Ltd (QNRX) is not a strong buy at the moment for a beginner investor focused on long-term gains. While the stock has shown a significant price increase recently and received positive FDA feedback for a key drug candidate, the technical indicators are neutral to bearish, financial performance is weak, and there are no strong proprietary trading signals or significant trading trends to support an immediate buy decision.
The MACD is negative and contracting, RSI is neutral at 47.154, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 6.101, and resistance is at 9.906. Overall, the technical indicators suggest a neutral to bearish outlook.
Positive FDA feedback indicating that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome. Analyst price target raised to $35 from $25, reflecting confidence in the company's potential.
Bearish technical indicators and no significant trading trends from hedge funds or insiders.
In Q4 2025, revenue remained at 0 with no growth, net income improved by 88.14% YoY but remains negative at -$4,348,373, and EPS dropped to 0, down 100% YoY. Gross margin showed no improvement.
Alliance Global raised the price target to $35 from $25 and maintained a Buy rating, citing higher valuation based on priority review vouchers.
